Definium Therapeutics, Inc.
DFTX
Rank in Stocks
#3750
Definium Therapeutics, Inc. operates as a clinical-stage biopharmaceutical firm... Definium Therapeutics, Inc. operates as a clinical-stage biopharmaceutical firm dedicated to developing innovative therapeutic solutions for various brain health and neurological disorders. Its pipeline features key experimental drug candidates like MM120, which is currently undergoing Phase 3 clinical trials for generalized anxiety disorder (GAD) and attention deficit hyperactivity disorder (ADHD). Another significant compound, MM402 – an R-enantiomer of 3,4-methylenedioxymethamphetamine – is in Phase 1 trials, targeting the fundamental symptoms of autism spectrum disorder. The company maintains its headquarters in New York, New York.
Share Price
$33.26
Last synced: 2026-10-19
Market Cap
$4.47B
Change (1 day)
3.60%
Change (1 year)
204.10%
Country
US
Trade Definium Therapeutics, Inc. (DFTX)
Category
Healthcare
Dividend yield history for Definium Therapeutics, Inc. (DFTX)
Definium Therapeutics, Inc. (stock symbol: DFTX) dividend yield (TTM) as of 2026: 0
Average dividend yield, last 5 years : 0.00%
Average dividend yield, last 5 years : 0.00%
Dividend yield history for Definium Therapeutics, Inc. (DFTX) from 2026 to 2026
Dividend Yield at the end of each year (TTM)
| Year | Dividend Yield | Change |
|---|---|---|
| Not enough data for the provided dates. | ||
Dividend yields (TTM) for similar companies or competitors
| Company | Dividend Yield | Country |
|---|---|---|
| 0.00% |
US
|
|
| 0.00% |
US
|
|
| 2.17% |
AU
|
|
| 0.00% |
CH
|
|
| 0.00% |
NL
|
